All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Georg-August-University Göttingen (UMG) and MRC Technology (MRCT), of London, signed an exclusive license to develop a therapy for neurodegenerative diseases based on antibody-targeting amyloid beta peptides.